Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Ninlaro Misses Mark In Transplant-Ineligible 1L Myeloma

Executive Summary

Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.

You may also be interested in...



Ninlaro Positive In Non-Transplant MM Maintenance

Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.

Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel